Sherif El Harazi
Ophthalmology · Glendale, CANPI 1982714887
Payments from drug & device makers
Across 672 payments — averaging $13,625 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3.1M
- Oyster Point Pharma, Inc.$1.2M
- Glaukos Corporation$1M
- Bausch & Lomb Americas Inc.$755K
- Alcon Research LLC$671K
- Novartis$631K
- plus $1.8M from 21 others
Across 9 payments — averaging $14,804 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch Health US, LLC$82K
- AbbVie$51K
What the payments were for
- Consulting fees$5007%
- Speaking & faculty fees$4,30059%
- Travel & lodging$591%
- Food & beverage$2,43033%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 194 | $3,050,759 |
| Oyster Point Pharma, Inc. | 34 | $1,218,947 |
| Glaukos Corporation | 62 | $1,007,945 |
| Bausch & Lomb Americas Inc. | 5 | $755,474 |
| Alcon Research LLC | 24 | $671,240 |
| Novartis | 28 | $631,269 |
| Roche TCRC, Inc. | 24 | $429,074 |
| Bausch Health US, LLC | 21 | $302,638 |
| Kala Pharmaceuticals, Inc. | 14 | $171,765 |
| Astrazeneca UK Limited | 1 | $168,560 |
| Boehringer Ingelheim International GmbH | 148 | $142,011 |
| Padagis US LLC | 6 | $132,100 |
| Boehringer Ingelheim | 12 | $124,817 |
| Genentech, Inc. | 7 | $111,614 |
| Dompe Farmaceutici S.p.a. | 6 | $93,598 |
| Perrigo Company PLC | 3 | $58,300 |
| Hoffmann-la Roche Limited | 5 | $41,332 |
| Mallinckrodt Hospital Products Inc. | 5 | $16,772 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $10,362 |
| Shire North American Group Inc | 8 | $6,446 |
| Mallinckrodt Enterprises LLC | 1 | $5,000 |
| Dompe US, Inc. | 4 | $4,400 |
| Aerie Pharmaceuticals, Inc. | 49 | $930 |
| Bioverativ Therapeutics Inc. | 1 | $500 |
| Sun Pharmaceutical Industries Inc. | 6 | $135 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $98 |
| Akorn, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Oxervate$1,500
How this compares
$9,156,109 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Latanoprost | 58 | $521 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Glendale
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
- Steven JacobsonLos Angeles$4.7M
- Peter WinArcadia$4.2M
- John CarlsonRiverside$4.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.